The 5-HT3-receptor antagonists (granisetron, ondansetron) play a prominent role in the management of nausea and vomiting caused by chemotherapeutic agents. Their use is considered appropriate in patients receiving chemotherapy with high or moderately high emetogenic potential. Using these drugs at their lowest effective dose helps reduce their cost. Trials comparing granisetron with ondansetron generally indicate that a single intravenous (IV) dose of granisetron is as effective as multiple or single doses of IV ondansetron. Both drugs are well tolerated. The addition of dexamethasone can enhance the benefits of 5-HT3-receptor antagonist therapy.
|Original language||English (US)|
|Journal||P and T|
|Issue number||3 SUPPL.|
|State||Published - Jan 1 1996|
ASJC Scopus subject areas
- Pharmacology (medical)